Derm Research, PLLC
18
0
0
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 5/100
11.1%
2 terminated/withdrawn out of 18 trials
88.2%
+1.7% vs industry average
83%
15 trials in Phase 3/4
107%
16 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel
Role: collaborator
A Pilot Study on the Use of Seysara for Rosacea
Role: lead
The Maintenance Effect of Enstilar Foam in Combination With Otezla
Role: lead
The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients
Role: lead
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis
Role: collaborator
A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque Psoriasis
Role: collaborator
The Use of Oracea and Epiduo Forte in Severe Acne Patients
Role: lead
Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris
Role: lead
The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color
Role: lead
Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy
Role: lead
Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis
Role: lead
Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study
Role: lead
Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel
Role: lead
Management of Pruritus With Xyzal in Atopic Dermatitis
Role: lead
A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis
Role: lead
Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)
Role: lead
Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)
Role: lead
A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis
Role: lead
All 18 trials loaded